Latest News

Quanta Services (PWR) is back in focus after new grid modernization and energy transition contracts helped push its project backlog to a record level, just as investors look ahead to the upcoming Q4 2025 earnings release. See our latest analysis for Quanta Services. The recent contract wins, record backlog and expectations for the upcoming Q4 2025 results come on top of a multi month rally, with a 30 day share price return of 8.63% and a 1 year total shareholder return of 29.61%. This...

Zions Bancorporation, National Association reported past fourth-quarter 2025 earnings with net interest income of US$683 million and net income of US$263 million, lifting diluted EPS from continuing operations to US$1.76 versus US$1.34 a year earlier. For 2025 as a whole, the bank’s net income rose to US$899 million and diluted EPS to US$6.01, alongside expanding net interest margin, strong deposit growth, and stable credit quality that collectively strengthened its capital position. We’ll...

Perella Weinberg Partners (PWP) is in focus after announcing a board leadership transition, with founder Peter A. Weinberg set to step down as Chairman and CEO Andrew Bednar preparing to assume the Chairman role. See our latest analysis for Perella Weinberg Partners. The leadership transition news comes as Perella Weinberg Partners’ share price has moved to US$21.60, with a 30 day share price return of 24.14% and a 3 year total shareholder return of 129.20%. This suggests longer term...

Corvus Pharmaceuticals recently reported positive results from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 trial of oral soquelitinib in moderate to severe atopic dermatitis, and confirmed plans to start a Phase 2 study in the first quarter of 2026. The cohort 4 data are particularly interesting because they show clinical activity in patients who had previously failed systemic treatments, including dupilumab and JAK inhibitors, while maintaining a favorable safety profile...

In November 2025, uniQure disclosed that the FDA found data from its Phase I/II AMT-130 Huntington’s disease studies insufficient to support a Biologics License Application, and later feedback questioned the adequacy of its external-control dataset for accelerated approval. This setback highlights how emerging regulatory expectations around evidence standards can materially affect the development path of gene therapies even when early efficacy signals appear encouraging. We’ll now examine...

Aurelia Metals has released its December 2025 quarterly update and Q2 2026 results, reporting strong multi-metal production, solid cash generation, and reaffirmed FY26 guidance alongside ongoing ramp-up at the Federation Mine and expansions at Great Cobar and Peak. An interesting angle for investors is how the ahead-of-plan Federation ramp-up and promising Nymagee and Federation drilling results may underpin future capacity growth and resource potential. We’ll now explore how Aurelia Metals’...

In recent months, Packaging Corporation of America has benefited from growing optimism about a recovery in the packaging cycle, supported by disciplined containerboard pricing and management’s focus on high-return mill investments. What stands out is the company’s decision to emphasize cost efficiency and cash returns to shareholders instead of pursuing large acquisitions, signaling a measured approach to capital allocation. Next, we’ll examine how this emphasis on disciplined pricing...

Entergy (ETR) is back in focus after several Wall Street firms reiterated or upgraded their views, pointing to expectations for sustained EPS growth supported by industrial and data center demand and constructive regulation. See our latest analysis for Entergy. At a share price of US$94.75, Entergy’s recent 30 day share price return of 3.55% contrasts with a softer 90 day share price return of a 1.30% decline. A 1 year total shareholder return of 16.51% sits alongside very strong 3 and 5 year...

Galderma Group (SWX:GALD) is back in focus after announcing fresh clinical and real world data for its neuromodulators Relfydess and Dysport at the TOXINS 2026 International Conference in Madrid. See our latest analysis for Galderma Group. The fresh neuromodulator data arrives after a softer near term patch for the stock, with a 30 day share price return of 5.53% and a 7 day share price return of a 3.21% decline, even though the 90 day share price return is 12.84% and the 1 year total...

What Sun Communities’ recent performance might be telling investors Sun Communities (SUI) has drawn attention after a recent move that left its shares around $125.99, with total return over the past year at about 5%, and roughly flat performance over the past 3 years. See our latest analysis for Sun Communities. The recent 1 day share price decline of about 3.3% comes after a 30 day share price return of 2.7% and a 1 year total shareholder return of roughly 5%, suggesting only modest momentum...

Service Corporation International (SCI) has been in focus after its latest quarter showed 4.4% year on year revenue growth, topping analyst expectations by 1.5%, while recent positive Wall Street coverage has added another layer of investor attention. See our latest analysis for Service Corporation International. The share price, which closed at $82.35, has had a 5.3% 30 day share price return and a 6.7% year to date share price return. The 5 year total shareholder return of 66.1% points to...

In January 2026, Blue Moon Group Holdings Limited announced earnings guidance indicating it expects at least a 50% reduction in its loss attributable to equity holders for 2025 compared with the approximately HK$749.30 million loss recorded for 2024. The company attributes this anticipated improvement to tighter cost optimisation, streamlined operations and continued investment in new product promotion and channel expansion, particularly for concentrated liquid laundry detergents. Next, we...

West Pharmaceutical Services recently announced at Pharmapack 2026 in Paris the global commercial availability of its West Synchrony S1 prefillable syringe system, offering multiple configurations tailored for biologics and vaccines. An interesting angle is how Synchrony S1 expands West’s presence in integrated drug-device delivery solutions at a time of rising combination-product demand. Next, we’ll examine how this Synchrony S1 launch shapes West’s broader investment narrative around...

Disc Medicine recently faced a two-week postponement of the U.S. FDA’s review of its rare disease candidate bitopertin, as regulators raised questions about efficacy endpoints, data integrity, and potential abuse risk. At the same time, the company appointed industry veteran Lisa Amaya Price as Chief Human Resources Officer, signaling an effort to strengthen its organizational backbone as it prepares for possible commercialization. Next, we’ll examine how the FDA’s temporary review delay for...

Lonking Holdings Limited recently issued earnings guidance for the year ended December 31, 2025, expecting net profit of about RMB 1,250 million to RMB 1,330 million, implying a significant increase of 23% to 31% versus the prior year. The company attributes this stronger profitability to growth in domestic and export sales, a larger contribution from high-value-added new products, and successful efforts to improve quality, control costs, and lift overall gross profit margins. Next, we will...

Sonic Healthcare (ASX:SHL) is back on investors’ radar after a 15.0% share price decline since the start of 2025, prompting fresh questions about its valuation and the role of its long-running dividend program. See our latest analysis for Sonic Healthcare. The recent 15.0% share price decline since the start of 2025 sits alongside a 1-month share price return of 3.06% and a 90-day share price return of 8.03%. However, the 1-year total shareholder return of a 12.94% decline shows that, despite...

First Capital REIT announced a 2.5% increase in its annualized cash distribution to $0.912 per unit, with the January 2026 payout of $0.076 per unit scheduled for February 16, 2026 to unitholders of record as of January 30, 2026. This distribution increase highlights management’s confidence in the REIT’s cash flow profile and may appeal to income-focused investors in Canada’s retail real estate sector. We’ll now examine how this 2.5% distribution increase shapes First Capital REIT’s...

Reverse split reshapes Ozop Energy Solutions share structure Ozop Energy Solutions (OZSC) is carrying out a 1 for 5,000 reverse stock split effective January 21, 2026. This move sharply consolidates its share count and changes the trading price per share. This type of corporate action does not alter the company’s reported revenue of US$0.32 million or its loss of US$6.95 million, but it can influence liquidity, trading behavior, and how different investors view the stock. See our latest...

In recent days, Genentech, a member of the Roche Group, announced it will more than double its planned investment in a new Holly Springs, North Carolina biomanufacturing facility to about US$2.00 billion, aiming to produce next-generation treatments for metabolic conditions such as obesity by 2029 and support more than 2,000 jobs. This expanded commitment also forms part of Roche and Genentech’s broader US$50.00 billion U.S. manufacturing pledge, highlighting how scale in advanced production...

Earlier in January 2026, Citi and JPMorgan published upbeat research on China’s life insurance industry, highlighting wealth reallocation, stable margins and stronger fundamentals across Asian insurers. Both banks singled out China Life Insurance as a preferred industry leader, suggesting it could be a key beneficiary of any sector-wide re-rating and regulatory-driven divergence. Next, we’ll examine how this supportive analyst sentiment, particularly around wealth reallocation into insurance...

Some investors may be wondering whether Workday is starting to look interesting at its current price, or whether the shares still carry a premium that is hard to justify. After closing at US$182.99, the stock has seen a 16.3% decline over the last 30 days and a 27.0% decline over the last year. These moves may have changed how some investors think about its growth potential and risk. Recent coverage has focused on Workday's position in enterprise software and its ongoing push to win and...

Samsung Electronics (KOSE:A005930) used CES 2026 to present its AI Promoter system, created with ESTsoft, for use in exhibition and event settings. The company introduced new Micro RGB TVs and Odyssey gaming monitors, alongside audio products positioned for premium home entertainment and gaming setups. Samsung announced a partnership with UnionPay International to expand integrated mobile payment options within its ecosystem. For a company already active across semiconductors, consumer...

Lerøy Seafood Group ASA recently reported its fourth-quarter and full-year 2025 operating results, showing lower Q4 salmon, trout, and wild catch volumes than a year earlier, but higher annual harvested volumes of salmon and trout. The contrast between softer quarterly output and stronger full-year salmon and trout production gives investors a more nuanced view of Lerøy’s operational momentum. We will now explore how this mix of reduced quarterly volumes and higher annual salmon and trout...

Perseus Mining has reported that a second contractor employee has died following an offsite vehicle accident near its Bagoé Gold Mine in Côte d’Ivoire, with other passengers treated for minor injuries and released from hospital, and investigations continuing with Ivorian authorities. The tragedy puts a spotlight on Perseus Mining’s safety culture and contractor oversight, raising questions about how it manages social and operational risks across its sites. We’ll now examine how this...